Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial

INTRODUCTION: Anlotinib has brought about marked progression-free survival and overall survival benefit compared with placebos as third-line or further treatment in advanced NSCLC. Nevertheless, the safety and efficacy of concurrent anlotinib and chemoradiotherapy are still unclear. METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hui, Jia, Wenxiao, Jing, Xuquan, Huang, Wei, Wang, Linlin, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160472/
https://www.ncbi.nlm.nih.gov/pubmed/35663415
http://dx.doi.org/10.1016/j.jtocrr.2022.100339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160472/
https://www.ncbi.nlm.nih.gov/pubmed/35663415
http://dx.doi.org/10.1016/j.jtocrr.2022.100339

Ejemplares similares